Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $873.83 million. The enterprise value is $503.35 million.
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025, after market close.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 105.79 million shares outstanding. The number of shares has increased by 26.59% in one year.
| Current Share Class | 105.79M |
| Shares Outstanding | 105.79M |
| Shares Change (YoY) | +26.59% |
| Shares Change (QoQ) | +0.42% |
| Owned by Insiders (%) | 11.14% |
| Owned by Institutions (%) | 72.16% |
| Float | 88.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 35.53 |
| PB Ratio | 6.49 |
| P/TBV Ratio | 7.61 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.82, with a Debt / Equity ratio of 0.26.
| Current Ratio | 3.82 |
| Quick Ratio | 3.26 |
| Debt / Equity | 0.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -295.94% and return on invested capital (ROIC) is -201.13%.
| Return on Equity (ROE) | -295.94% |
| Return on Assets (ROA) | -103.41% |
| Return on Invested Capital (ROIC) | -201.13% |
| Return on Capital Employed (ROCE) | -219.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.00M |
| Employee Count | 256 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $859,000 in taxes.
| Income Tax | 859,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.63% in the last 52 weeks. The beta is 3.45, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.45 |
| 52-Week Price Change | -84.63% |
| 50-Day Moving Average | 15.13 |
| 200-Day Moving Average | 20.26 |
| Relative Strength Index (RSI) | 25.57 |
| Average Volume (20 Days) | 4,468,047 |
Short Selling Information
The latest short interest is 10.30 million, so 9.74% of the outstanding shares have been sold short.
| Short Interest | 10.30M |
| Short Previous Month | 13.19M |
| Short % of Shares Out | 9.74% |
| Short % of Float | 11.66% |
| Short Ratio (days to cover) | 4.02 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -937.36M |
| Pretax Income | -766.11M |
| Net Income | -766.97M |
| EBITDA | -928.68M |
| EBIT | -937.36M |
| Earnings Per Share (EPS) | -$7.65 |
Full Income Statement Balance Sheet
The company has $404.98 million in cash and $34.49 million in debt, giving a net cash position of $370.49 million or $3.50 per share.
| Cash & Cash Equivalents | 404.98M |
| Total Debt | 34.49M |
| Net Cash | 370.49M |
| Net Cash Per Share | $3.50 |
| Equity (Book Value) | 134.59M |
| Book Value Per Share | 1.27 |
| Working Capital | 350.50M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$645.08 million and capital expenditures -$1.35 million, giving a free cash flow of -$646.43 million.
| Operating Cash Flow | -645.08M |
| Capital Expenditures | -1.35M |
| Free Cash Flow | -646.43M |
| FCF Per Share | -$6.11 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.59% |
| Shareholder Yield | -26.59% |
| Earnings Yield | -87.77% |
| FCF Yield | -73.98% |
Dividend Details Analyst Forecast
The average price target for Biohaven is $38.07, which is 360.90% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.07 |
| Price Target Difference | 360.90% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -49.98% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |